Kandavel Shanmugam
Overview
Explore the profile of Kandavel Shanmugam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
449
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Yoon H, Shi Q, Heying E, Muranyi A, Bredno J, Ough F, et al.
Clin Cancer Res
. 2018 Oct;
25(1):125-133.
PMID: 30301825
Purpose: Colorectal cancers with deficient DNA mismatch repair (dMMR) are presumed to uniformly have dense lymphocytic infiltration that underlies their favorable prognosis and is critical to their responsiveness to immunotherapy,...
12.
Ghosh P, Tie J, Muranyi A, Singh S, Brunhoeber P, Leith K, et al.
Clin Cancer Res
. 2016 Apr;
22(14):3488-98.
PMID: 27029492
Purpose: Prognostic markers that identify patients with stage II colon cancers who are at the risk of recurrence are essential to personalize therapy. We evaluated the potential of GIV/Girdin as...
13.
Lopez-Sanchez I, Dunkel Y, Roh Y, Mittal Y, De Minicis S, Muranyi A, et al.
Nat Commun
. 2014 Jul;
5:4451.
PMID: 25043713
Progressive liver fibrosis is characterized by the deposition of collagen by activated hepatic stellate cells (HSCs). Activation of HSCs is a multiple receptor-driven process in which profibrotic signals are enhanced...
14.
Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, et al.
Target Oncol
. 2014 May;
10(1):99-109.
PMID: 24859797
The B-type Raf kinase (BRAF) V600E mutation is a well-established biomarker for poor prognosis in metastatic colorectal cancer (mCRC) and is a highly attractive drug target. A barrier to the...
15.
Sinicrope F, Smyrk T, Tougeron D, Thibodeau S, Singh S, Muranyi A, et al.
Cancer
. 2013 May;
119(15):2765-70.
PMID: 23657789
Background: A point mutation (V600E) in the BRAF oncogene is a prognostic biomarker and may predict for nonresponse to anti-EGFR antibody therapy in patients with colorectal carcinoma. BRAFV600E mutations are...
16.
Marafioti T, Copie-Bergman C, Calaminici M, Paterson J, Shende V, Liu H, et al.
Histopathology
. 2013 Mar;
62(6):860-75.
PMID: 23509938
Aims: The aim of this study was to analyse the immunophenotypic and molecular features of a large series of follicular lymphomas, focusing in particular on atypical cases that fail to...
17.
Singh P, Behrens M, Eggers J, Cerny R, Bailey J, Shanmugam K, et al.
J Biol Chem
. 2008 Jul;
283(40):26985-95.
PMID: 18625714
MUC1, a transmembrane mucin, is a key modulator of several signaling pathways that affect oncogenesis, motility, and cell morphology. The interaction of MUC1 cytoplasmic tail (MUC1CT) with signal transducers and...
18.
Singh P, Wen Y, Swanson B, Shanmugam K, Kazlauskas A, Cerny R, et al.
Cancer Res
. 2007 Jun;
67(11):5201-10.
PMID: 17545600
MUC1 is a heterodimeric transmembrane glycoprotein that is overexpressed and aberrantly glycosylated in ductal adenocarcinomas. Differential phosphorylation of the MUC1 cytoplasmic tail (MUC1CT) has been associated with signaling events that...
19.
Thompson E, Shanmugam K, Hattrup C, Kotlarczyk K, Gutierrez A, Bradley J, et al.
Mol Cancer Res
. 2006 Jul;
4(7):489-97.
PMID: 16849524
Much of the ability of the MUC1 oncoprotein to foster tumorigenesis and tumor progression likely originates from the interaction of its cytoplasmic tail with proteins involved in oncogenic signaling. Many...